Why Do Iron Pills Cause Constipation? The Colonic Fenton Mechanism

Quick Answer: It's About Unabsorbed Iron, Not Iron Itself

Iron pills cause constipation when a large fraction of the ingested dose passes through the small intestine unabsorbed and reaches the colon as free Fe²⁺ ions. There, Fe²⁺ catalyses the Fenton reaction (Fe²⁺ + H₂O₂ → Fe³⁺ + OH• + OH⁻), generating hydroxyl radicals that damage colonocytes. The colon responds by slowing motility and increasing water reabsorption — producing harder, less frequent stools.

The critical variable is how much iron reaches the colon, which depends on the iron form, dose, and absorption pathway.

The Colonic Fenton Mechanism: Step by Step

Here is what happens physiologically when you take an iron salt like ferrous sulfate:

Step 1: DMT1 Saturation in the Duodenum

Non-chelated iron salts (ferrous sulfate, fumarate, gluconate) release free Fe²⁺ ions in the acidic stomach environment. These ions are absorbed in the duodenum via the DMT1 (divalent metal transporter 1) channel. But DMT1 has a saturation ceiling — it can only transport a limited amount of Fe²⁺ per dose window.

At a standard 65 mg elemental iron dose (from 200 mg ferrous sulfate), DMT1 absorbs roughly 8–12 mg. The remaining 53–57 mg passes unabsorbed into the jejunum, ileum, and ultimately the colon.

Step 2: Fenton Reactions in the Colon

Once free Fe²⁺ reaches the colon, it encounters hydrogen peroxide (H₂O₂) — a normal byproduct of aerobic bacterial metabolism. As described by Carrier et al. (2001) and confirmed in the Tolkien et al. (2015) meta-analysis of 43 trials, the Fenton reaction generates hydroxyl radicals (OH•), one of the most reactive oxygen species in biology:

These radicals damage the colonic mucosal lining — injuring epithelial cells, disrupting the mucus barrier, and triggering local inflammation.

Step 3: Protective Motility Slowdown

In response to oxidative mucosal damage, the colon reduces peristalsis (the rhythmic contractions that move stool forward) and increases water reabsorption. Carrier et al. (2001) demonstrated that oral iron supplementation significantly increased markers of colonic oxidative stress — including lipid peroxidation (measured by faecal TBARS) — and was associated with prolonged colonic transit times. This is a protective reflex: the colon slows transit to limit further exposure of damaged tissue to reactive oxygen species. The clinical result: harder stools, reduced frequency, and the subjective feeling of constipation.

DMT1 Saturation Math: How Much Iron Actually Reaches Your Colon?

This is the calculation that explains why iron form matters for constipation:

The key insight: ferrous bisglycinate delivers more absorbed iron (11 mg vs 7–8 mg) while sending less than half the unabsorbed iron to the colon (25 mg vs 57–58 mg). This is because it uses a dual absorption pathway — the PepT1 peptide transporter recognises the glycine-chelated iron as a dipeptide, bypassing DMT1 saturation.

Zimmermann 2010: How Colonic Iron Disrupts Your Gut Microbiota

Beyond the direct Fenton damage, unabsorbed colonic iron has a second mechanism of harm — dysbiosis.

Zimmermann et al. (2010) demonstrated in a controlled study that iron fortification significantly altered the colonic microbiome:

• Pathogenic Enterobacteriaceae (including E. coli) increased significantly
• Protective Lactobacillus populations decreased
• Faecal calprotectin (an inflammation marker) increased, indicating subclinical colonic inflammation

This matters for constipation because Lactobacillus species produce short-chain fatty acids (SCFAs) — particularly butyrate — that regulate colonic motility and water balance. When Lactobacillus declines and Enterobacteriaceae dominate, the colon loses its motility-regulating SCFA supply, compounding the Fenton-mediated motility slowdown.

The practical implication: reducing the colonic iron load (by choosing a form with higher fractional absorption) protects both the mucosal lining and the microbiome.

Why Timing and Dose Splitting Don't Fully Solve It

Stoffel et al. (2017) showed that a single iron dose triggers a hepcidin surge within 6–8 hours that blocks ferroportin on enterocytes, reducing absorption of a second dose by ~35–45%. This has led to alternate-day dosing protocols.

However, alternate-day dosing only improves fractional absorption — it does not change the fundamental problem: non-chelated forms still saturate DMT1 per dose, and the unabsorbed remainder still reaches the colon. Alternate-day dosing with ferrous sulfate reduces the frequency of colonic iron exposure but not the per-dose colonic burden.

The more effective strategy is choosing a form that absorbs more per dose through a dual pathway (DMT1 + PepT1), so less iron reaches the colon in the first place.

If Constipation Is Your Main Barrier to Continuing Iron

If constipation has been the reason you stopped or reduced your iron supplement, the evidence points to two actionable steps:

• Discuss with your doctor whether switching to a chelated iron form (lower colonic burden) could resolve the symptom
• Evaluate iron supplements that use ferrous bisglycinate — which uses both DMT1 and PepT1 pathways, achieving higher absorption at lower doses

In that context, Hemascore (36 mg elemental iron from ferrous bisglycinate, with Vitamin C, active B12, and active folate) is one formulation designed specifically to minimise the colonic iron load that drives Fenton-mediated constipation.